Curza
Cūrza is a small-molecule therapeutics company focused on developing proprietary drugs to combat infectious diseases and antibiotic resistance. Their mission is to address the global threat of antimicrobial resistance by creating novel classes of antibiotics, including broad-spectrum antibiotics targeting drug-resistant bacteria and antibiofilm agents. The company is dedicated to protecting global health through innovative research, development, and collaboration with institutions like the University of Utah. Cūrza's vision is to lead the fight against antibiotic-resistant pathogens and biofilm-related infections with cutting-edge therapies.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Lead ribosome‑targeting antibiotic program (preclinical)
A preclinical program centered on a novel class of ribosome‑targeting small molecules designed to address drug‑resistant Gram‑negative and ESKAPE pathogens by binding a previously unexploited ribosomal site.
Antibiofilm antibiotic series
A series of compounds developed to specifically target and eradicate bacterial biofilms for use against chronic and device‑related biofilm infections.
Lead ribosome‑targeting antibiotic program (preclinical)
A preclinical program centered on a novel class of ribosome‑targeting small molecules designed to address drug‑resistant Gram‑negative and ESKAPE pathogens by binding a previously unexploited ribosomal site.
Antibiofilm antibiotic series
A series of compounds developed to specifically target and eradicate bacterial biofilms for use against chronic and device‑related biofilm infections.
Services
Partnerships and collaborative research with academic and government institutions to advance preclinical antibiotic and antibiofilm programs, supported by federal and non‑dilutive funding.
Design and execution of assay cascades including whole‑cell phenotypic screens, biochemical assays and MIC testing to identify and characterize antibacterial leads.
Support for acquiring and managing federal and non‑dilutive funding (e.g., NIH, DTRA, SBIR) and overseeing multi‑institutional research collaborations.
Partnerships and collaborative research with academic and government institutions to advance preclinical antibiotic and antibiofilm programs, supported by federal and non‑dilutive funding.
Design and execution of assay cascades including whole‑cell phenotypic screens, biochemical assays and MIC testing to identify and characterize antibacterial leads.
Support for acquiring and managing federal and non‑dilutive funding (e.g., NIH, DTRA, SBIR) and overseeing multi‑institutional research collaborations.
Expertise Areas
- Antibiotic discovery and development
- Antibiofilm therapeutics
- Medicinal chemistry and synthetic chemistry
- Microbiology and biofilm infection models
Key Technologies
- Small‑molecule therapeutics
- Ribosome‑binding antibiotic mechanisms
- Antibiofilm compound technology
- Whole‑cell phenotypic screening
News & Updates
Salt Lake City, April 1, 2021: Cūrza and the University of Florida expand their collaboration to include bacterial biothreats, supported by a DTRA award.
Salt Lake City, Utah, July 25, 2019: Cūrza announces a $5.25 million investment from the Novo Holdings’ REPAIR Impact Fund.
Salt Lake City, Utah, July 1, 2016: Cūrza awarded Phase 1 SBIR to develop new antibiotics targeting drug-resistant bacteria.
Salt Lake City, Utah, July 1, 2016: Cūrza awarded an R01 grant to advance new antibiotics targeting drug-resistant bacteria.
Proceeds to fund development of Wound VAC infection model, Salt Lake City, 2016.
Salt Lake City, April 1, 2021: Cūrza and the University of Florida expand their collaboration to include bacterial biothreats, supported by a DTRA award.
Salt Lake City, Utah, July 25, 2019: Cūrza announces a $5.25 million investment from the Novo Holdings’ REPAIR Impact Fund.
Salt Lake City, Utah, July 1, 2016: Cūrza awarded Phase 1 SBIR to develop new antibiotics targeting drug-resistant bacteria.
Salt Lake City, Utah, July 1, 2016: Cūrza awarded an R01 grant to advance new antibiotics targeting drug-resistant bacteria.
Proceeds to fund development of Wound VAC infection model, Salt Lake City, 2016.